Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality
and disability in allogeneic hematopoietic cell transplantation recipients and a major …

Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk
haematological malignant disorders and other life-threatening haematological and genetic …

Although transplant practices have changed over the last decades, no information is
available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) …

Risk factors for grades 2-4 acute graft-versus-host disease (GVHD) and for chronic GVHD as
defined by National Institutes of Health consensus criteria were evaluated and compared in …

This consensus document is intended to serve 3 functions. First, it standardizes the criteria
for diagnosis of chronic graft-versus-host disease (GVHD). Second, it proposes a new …

The best donor for a related donor for a human leukocyte antigen (HLA) haplotype-
mismatched transplant for hematological neoplasms is controversial. We studied outcomes …

Chronic graft-versus-host disease (GVHD) remains a vexing and dangerous complication of
allogeneic stem cell transplantation. Mild forms of chronic GVHD are often manageable with …

The National Marrow Donor Program (NMDP) maintains a registry of approximately 4 million
volunteer unrelated donors for patients in need of a stem cell transplant. When several …

More than 25,000 hematopoietic stem cell transplantations (HSCTs) are performed each
year for the treatment of lymphoma, leukemia, immune-deficiency illnesses, congenital …

Cytomegalovirus (CMV) infection and graft-versus-host disease (GVHD) are important
complications after allogeneic hematopoietic stem cell transplantation (HSCT) with a clear …